Home/Pipeline/Oral Encapsulated GLP-1

Oral Encapsulated GLP-1

Obesity

PreclinicalActive - Program advancement

Key Facts

Indication

Obesity

Phase

Preclinical

Status

Active - Program advancement

Company

Poolbeg Pharma

About Poolbeg Pharma

Poolbeg Pharma is a UK-based, AIM-listed biotech founded in 2021 with a mission to develop high-value therapies for large markets with unmet needs. Its strategy centers on a capital-efficient model of de-risking assets through early clinical development before pursuing partnerships. Key achievements include securing FDA Orphan Drug Designation for its lead oncology asset, POLB 001, and building a proprietary AI discovery platform powered by unique human challenge trial data. The company aims to accelerate pipeline growth while minimizing substantial capital expenditure.

View full company profile

Therapeutic Areas

Oncology Supportive Care Metabolic Disease (Obesity)Infectious Disease

Other Obesity Drugs

Drug	Company	Phase	Status
LET003	Harbour BioMed	Discovery	Active (Global)
LET001	Harbour BioMed	Discovery	Active (Global)
RGT-075	Regor Therapeutics	Phase 2b	Active
Anti‑Obesity Oral Drug	Premas Biotech	Phase 1	Active
Obesity Target Discovery Collaboration	Fauna Bio	Target Discovery/Preclinical	Active
GLP-1 variants	Heligenics	Discovery	Active
MYO Platform (Metabolic Disease)	Renbio	Pre-clinical	Active
Obesity Clinical Trials	IMA Clinical Research	Not Applicable (Service)	Active
KAYO-2000	KayoThera	Preclinical	Active
MVD-1 (SANA)	Eolo Pharma	Phase 1	Active
GIP-neutralizing antibody	Helicore Biopharma	Pre-clinical	Active
Antral Gastroplasty / Endoscopic Sleeve	Endo-TAGSS	Pre-clinical	Active